四项肿瘤标志测定对肺癌诊断和病情评估的临床价值
The Value Of Measurement Of 4 Tumor Markers For Diagnosis And Evaluation Of Disease Extent In Patiets With Lung Cancer
-
摘要: 目的: 评价血清CEA 、CA50 、CA19-9 和CA125水平对肺癌诊断和病情评估的临床价值。方法: 测定了62例肺癌患者血清CEA 、CA50 、CA19-9 和CA125水平, 并观察了其中58例患者血清该四项肿瘤标志水平在不同TNM分期以及治疗前后的变化。结果: 肺癌组患者CEA 、CA50和CA19-9 水平明显高于正常对照组和良性肺病组。CA125 血清水平在肺癌组和良性肺病组之间无显著差异。TNM临床分期越晚, CEA 、CA50 、CA19-9 和CA125水平越高。手术治疗和化疗有效的患者, 该四项肿瘤标志水平降低, 病情进展和肿瘤转移患者则升高。结论: 该四项肿瘤标志在肺癌的诊断(除外CA125), 病情监测和疗效判断方面可为临床提供有价值的资料。Abstract: Objective: To evaluat the value of measurement of 4 tumor markers (CEA, CA50, CA19-9, CA125) for diagnosis and evaluation of disease extent in patients with lung cancer. Methods: These tumor markers in serum were measured in 62 patients with lung cancers, and change of the markers were observed in 58 patients with different stage and after or before treatment. Results: Combination of these tumor markers increased sensitivity and accuracy of measurement, the most offective combination seemed to be CEA puls CA50 and CA19-9. The serum levels of the markers in patients with advanced disease (stage Ⅲ and Ⅳ) were significantly higher than in those with stage Ⅰ and Ⅱ. After surgery and chemotherapy (curative effects :CRPR), the serum levels of the markers in pafients was decrease significantly. Conclusion: Measurement of CEA, CA50 and CA19-9 in serum provide useful informafion for diagnosis and evaluation of disease extent in patients with lung cancer.
-
Key words:
- lung cancer /
- CEA /
- CA50 /
- CA19-9 /
- CA125
-
-
[1] Mitsuhashi N, Takahashi T, Sakruaih, etal. Establishment and characterization of a new human lung poorly differentiated adenocarcinoma cell line, Gll-1 producing carcinoembryonic antigen (CEA)and CA19-9. Lung Cancer, 1995, 12: 13; [2] Sakamoto K , Haga Y, Yoskimuera R, etal. Comparative effectiveness of the tumor diagnotic, CA19-9 CA125 and Carcinoembryonic antigen in patients with disease of the digestive system. Gut, 1987, 28: 323; [3] Holmgrem J, Lindholm L, Persson B, etal. Detection by monoclonal antibody of carbohydrateantigen CA50 in serum of patients with carcinoma. Br Med J,1984, 288: 1479; [4] Ohshio G, Yamaki K, Imamura T, etal. Di stribution the carbohydrate antigens, Du-PA N-2 and CA19-9 in tumors of the lung. Tumori, 1995, 8: 67; [5] Kimuru Y, Fujii T, Hamanoto K, etal. Serum CA125 level is a good prognostic indicator in lung cancer. Br J Cancer, 1990, 62: 676.
计量
- 文章访问数: 1368
- HTML全文浏览量: 29
- PDF下载量: 565
下载:
